27411, a novel human PGP synthase
AssigneeMillennium Pharmaceuticals, Inc.
InventorRachel A. Meyers
Life of this patent
Estimating the term…
Abstract
The present invention relates to a newly identified human PGP synthase. The invention also relates to polynucleotides encoding the PGP synthase. The invention further relates to methods using the PGP synthase polypeptides and polynucleotides as a target for diagnosis and treatment in PGP synthase-mediated or -related disorders. The invention further relates to drug-screening methods using the PGP synthase polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the PGP synthase polypeptides and polynucleotides. The invention further relates to procedures for producing the PGP synthase polypeptides and polynucleotides.
Claims22
An isolated nucleic acid molecule selected from the group consisting of:
- a) a nucleic acid molecule comprising a nucleotide sequence which is at least 60% identical to the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, or the nucleotide sequences of the cDNA inserts of the plasmids deposited with ATCC as Patent Deposit Numbers PTA-2011 or PTA-2340, wherein said nucleotide sequence encodes a polypeptide having biological activity;
- b) a nucleic acid molecule comprising a fragment of at least 20 nucleotides of the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, or the nucleotide sequences of the cDNA inserts of the plasmids deposited with ATCC as Patent Deposit Numbers PTA-2011 or PTA-2340,
- c) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2, or the amino acid sequences encoded by the cDNA inserts of the plasmids deposited with ATCC as Patent Deposit Numbers PTA-2011 or PTA-2340;
- d) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, or the amino acid sequences encoded by the cDNA inserts of the plasmids deposited with ATCC as Patent Deposit Numbers PTA-2011 or PTA-2340, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:2, or the amino acid sequences encoded by the cDNA inserts of the plasmids deposited with ATCC as Patent Deposit Numbers PTA-20 11 or PTA-2340,
- e) a nucleic acid molecule which encodes a naturally occurring allelic variant of a biologically active polypeptide comprising the amino acid sequence of SEQ ID NO:2, or the amino acid sequences encoded by the cDNA inserts of the plasmids deposited with ATCC as Patent Deposit Numbers PTA-2011 or PTA-2340, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising the complement of SEQ ID NO:1 or SEQ ID NO:3 under stringent conditions;
- and
- f) a nucleic acid molecule comprising the complement of a), b), c), d), or e).
An isolated polypeptide selected from the group consisting of:
- a) a biologically active polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 60% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, or the nucleotide sequences of the cDNA inserts of the plasmids deposited with ATCC as Patent Deposit Numbers PTA-2011 or PTA-2340;
- b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, or the amino acid sequences encoded by the cDNA inserts of the plasmids deposited with ATCC as Patent Deposit Numbers PTA-2011 or PTA-2340, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising the complement of SEQ ID NO:1 or SEQ ID NO:3 under stringent conditions;
- and,
- c) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, or the amino acid sequences encoded by the cDNA inserts of the plasmids deposited with ATCC as Patent Deposit Numbers PTA-2011 or PTA-2340, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:2;
- and
- d) a polypeptide having at least 60% sequence identity to the amino acid sequence SEQ ID NO:2, wherein the polypeptide has biological activity.
Dependencies are inferred from the claim text.